Imagine a nation grappling with one of the world's largest populations of overweight adults, where millions are turning to powerful new drugs for a miracle weight loss fix—but at what cost to their health and society? That's the reality unfolding in India right now, as medications like Rybelsus, Mounjaro, and Wegovy spark a boom in demand, promising rapid results yet stirring up debates about safety, ethics, and long-term well-being. Let's dive into this fascinating yet cautionary tale, exploring how these drugs are reshaping India's approach to weight management and why experts are sounding alarms about their misuse.
Just 16 minutes ago, reports highlighted a surge in calls to Mumbai-based diabetologist Rahul Baxi—not from folks battling high blood sugar alone, but from young professionals desperate for slimming solutions. Picture a 23-year-old corporate worker, stressed about the 10 kilograms he packed on after landing a high-pressure job, mentioning how a buddy at the gym is already using 'weight-loss jabs.' Dr. Baxi declined to prescribe them, challenging the man: 'What happens after you drop those 10kg on this medication? Halt it, and the pounds creep back. Continue without physical activity, and you might shed muscle instead of fat. These aren't replacements for balanced eating or sustainable lifestyle shifts,' he advised.
Such exchanges are increasingly routine, reflecting a skyrocketing interest in these treatments across urban India, home to the planet's second-highest number of obese individuals and over 77 million with Type 2 diabetes. Initially crafted to manage diabetes, these agents are now celebrated as revolutionary weight reducers, delivering outcomes that outshine past options. But their rise has ignited tough discussions—on the necessity of expert oversight, the dangers of improper use, and the fuzzy boundary separating medical therapy from cosmetic enhancement.
And this is the part most people miss: These aren't your average diet pills. 'These represent the strongest weight-loss medications we've encountered. Countless others have appeared and vanished, but none rival these in potency,' notes Anoop Misra, director of Delhi's Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases, and Endocrinology.
Two newcomers are leading India's burgeoning obesity treatment sector. First, semaglutide, produced by Denmark's Novo Nordisk, available as Rybelsus (a pill) and Wegovy (an injection)—with Ozempic (another injectable) approved here for diabetes but not yet for weight issues. Second, tirzepatide from the U.S.'s Eli Lilly, branded as Mounjaro, mainly for diabetes but frequently repurposed for shedding pounds in India.
Both fall into the GLP-1 drug category—a group that replicates a body's natural hormone controlling hunger. To explain simply for beginners: GLP-1 medications slow down digestion and influence brain signals that regulate appetite, helping you feel satisfied sooner and remain full longer. Typically injected weekly into the arm, thigh, or abdomen, they tame food urges—and for Mounjaro, they also enhance metabolism and overall energy equilibrium.
Dosing begins low, gradually increasing to a steady level, with weight reduction often kicking in within a few weeks. However, physicians caution that most regain the lost weight within a year if they stop, as the body fights back against slimming and cravings resurface. Extended use sans exercise or resistance training could erode muscle mass along with fat.
Not all bodies react the same; many hit a ceiling after dropping about 15% of their body weight. Side effects can include mild issues like nausea and diarrhea, or more severe ones such as gallstones, pancreatitis, and muscle wasting. India's typical diet, heavy on carbs and light on protein, already contributes to sarcopenic obesity—think of it as losing muscle while accumulating fat—and shedding weight without enough protein or workouts can worsen this condition.
'Fueled by media buzz and social media hype, these medications have ignited a frenzy among wealthy Indians aiming to drop a few pounds,' Dr. Baxi observes.
But here's where it gets controversial: This craze was palpable at a recent medical gathering in Delhi, as recalled by a local doctor. 'Three months post-launch of a new drug, I'd helped around a hundred patients. Yet a peer claimed he'd assisted over a thousand—largely with smuggled injections from the black market.'
India's obesity drug industry has exploded from $16 million in 2021 to nearly $100 million currently—a sixfold increase in just five years, per research from Pharmarack. Novo Nordisk dominates with its semaglutide offerings, Rybelsus capturing almost two-thirds of the market since 2022. Eli Lilly's tirzepatide, launched this year as Mounjaro, climbed to India's second-top-selling branded medication by September, according to the same firm. Each monthly pen of injectables (covering four weekly doses) runs 14,000 to 27,000 rupees, or about $157 to $300—steep for many in India.
What we've witnessed so far might be just the beginning. By March, the patent on semaglutide (the key component in Ozempic and Wegovy) expires here, potentially flooding the market with cheaper generic alternatives and boosting accessibility. Investment bank Jefferies dubs this a 'magic pill moment' for India, forecasting a $1 billion semaglutide sector if pricing drops, adoption grows, and policies support it.
'What we've learned is that close to a dozen firms are poised with generic versions of Rybelsus, the oral option,' shares Sheetal Sapale, Pharmarack's vice-president. 'However, as costs decrease, the potential for misuse escalates too.'
Physicians share alarming anecdotes: Patients receiving high doses from unqualified gym instructors, nutritionists, or beauty salons. Online chemists ship medications after quick phone chats, skipping prescriptions. Cosmetologists promote 'wedding packages' for swift pre-marital slimming. Fears loom of counterfeit drugs infiltrating supply chains. Even federal minister Jitendra Singh urged vigilance on these novel treatments.
'One patient inquired if these new drugs could help his daughter slim down seven kilograms before her wedding—in just three months,' recounts Mumbai chest physician Bhaumik Kamdar. 'He wanted assurance that they truly deliver.'
A key hurdle in India, experts say, lies in societal views on excess weight—and how they influence slimming attitudes.
'Most overlook that obesity is a persistent, recurring ailment,' emphasizes Mumbai bariatric surgeon Muffazal Lakhdawala. 'Individuals with ongoing obesity often crash-diet, shed some, then rebound with even more.'
'Here, being overweight often gets equated with prosperity and good living. We've dodged the issue so thoroughly that it's become normalized.'
Obesity, warnings indicate, paves the way to numerous health woes. 'It's connected to at least 20 types of cancer, fertility problems, osteoarthritis, and fatty liver disease—now a top cirrhosis trigger,' Dr. Lakhdawala adds. Despite impacting nearly one in eight people worldwide, no global agreement exists on defining or categorizing obesity.
'The introduction of these drugs has shifted the narrative—obesity is increasingly viewed as a medical condition, not merely a choice. But is this a game-changer or just another way to medicalize everyday life?'
Medical professionals from various fields are now prescribing these for beyond obesity or diabetes.
Endocrinologists, diabetologists, cardiologists, and nephrologists offer them to obese patients to bolster heart and kidney health—such as before procedures like angioplasty or stenting.
Orthopedic specialists recommend them for pre-knee surgery weight reduction, while pulmonologists use them for sleep apnea sufferers, a condition causing breathing pauses during slumber. 'For those with sleep apnea who shun CPAP machines, these can aid by promoting weight loss, which enhances rest quality,' Dr. Kamdar explains.
Even weight-loss surgery is adapting to India's obesity surge. Operations jumped from 200 in 2004 to 40,000 in 2022—a 200-fold leap.
Surgeons like Dr. Lakhdawala oversee holistic programs: Patients on these drugs first consult endocrinologists, dietitians, and psychologists for three to six months. 'We prescribe medications thoughtfully,' he stresses. 'Non-responders or severe cases advance to surgery.'
His stern message to urban Indians chasing shortcuts: 'Reserve these for dangerous weight gain, not vanity. For minor losses of five or 10 kilograms?'
His straightforward counsel: 'Eliminate sugar—it's the ultimate culprit. Without that, any slimming won't stick. Incorporate four weekly exercise sessions, and you'll drop those 5-7kg naturally—no needles required.'
As we wrap up, ponder this: Are these drugs a lifeline for millions or a risky shortcut that distracts from real lifestyle changes? Could treating obesity as a disease empower patients, or does it let individuals off the hook for personal responsibility? Share your thoughts in the comments—do you agree these medications are overhyped, or do they represent medical progress? What controversies have you encountered in your own health journeys? We'd love to hear your opinions and spark a discussion!
